Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Bile Duct Cancer Pipeline Drugs Analysis Overview
Bile Duct Cancer (Cholangiocarcinoma) is a rare disease in which malignant cells form in the bile ducts that carry the digestive fluid, bile. BDC occurs mostly in people older than age 50, although it can occur at any age.
The Bile Duct Cancer Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Bile Duct Cancer.
The report also provides actionable insights into the clinical and commercial landscapes of Bile Duct Cancer drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Marketed) | Enzyme Inhibitor, Genes, Nucleic Acids & Related Components Inhibitor, Receptor Inhibitor, Protein & Peptide Inhibitor, and Receptor Antagonist |
Key Routes of Administration | Injection, Oral, and Topical, |
Key Molecule Types | Small Molecule and Biologic |
Top Sponsors (Marketed and Pipeline Drugs) | National Cancer Institute US, Eli Lilly and Co, Sun Yat-Sen University, F. Hoffmann-La Roche Ltd, Hutchison MediPharma Ltd, Zhongshan Hospital, AstraZeneca Plc, Fudan University, and Bayer AG |
Leading Marketed Drugs for Bile Duct Cancer
Some of the leading marketed drugs for Bile Duct Cancer are durvalumab, entrectinib, futibatinib, infigratinib phosphate, and ivosidenib.
Bile Duct Cancer Marketed Drugs Segmentation by Mechanism of Action
The key mechanisms of action for Bile Duct Cancer marketed drugs are enzyme inhibitor, genes, nucleic acids & related components inhibitor, receptor inhibitor, protein & peptide inhibitor, and receptor antagonist. The BDC treatment landscape mostly comprises enzyme inhibitors targeting tyrosine kinases.
Bile Duct Cancer Marketed Drugs Analysis, by Mechanism of Action
Buy the Full Report for More Insights Into The Bile Duct Cancer Marketed Drugs Moa, Download A Free Report Sample
Bile Duct Cancer Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for Bile Duct Cancer marketed drugs are injection, oral, and topical. The majority of marketed drugs for BDC are injection therapies, closely followed by oral drugs.
Bile Duct Cancer Marketed Drugs Analysis, by Routes of Administration
Buy The Full Report for More Insights Into The Bile Duct Cancer Marketed Drugs RoA, Download A Free Report Sample
Bile Duct Cancer Marketed Drugs Segmentation by Molecule Type
The majority of the marketed drugs for BDC are small molecules. Biologics are the latest entrants into the space.
Bile Duct Cancer Marketed Drugs Analysis, by Molecule Type
Buy the Full Report for More Molecule Type Insights Into The Bile Duct Cancer Marketed Drugs, Download A Free Report Sample
Leading Pipeline Drugs for Bile Duct Cancer
Some of the leading pipeline drugs of Bile Duct Cancer are Apatinib mesylate, APL-502, Bintrafusp alfa, and Cellular Immunotherapy for Biliary Tract Cancer.
Bile Duct Cancer Pipeline Drugs Segmentation by Mechanism of Action
Some of the key mechanisms of action for Bile Duct Cancer pipeline drugs are enzyme inhibitor, cytotoxic, protein & peptide inhibitor, receptor inhibitor, receptor antagonist, receptor agonist, biological factor inhibitor, genes, nucleic acids & related components inhibitor, biological factor activator, and antigen inhibitor. Around 23% of the BDC pipeline drugs are enzyme inhibitors.
Bile Duct Cancer Pipeline Drugs Analysis, by Mechanisms of Action
Buy The Full Report for More Moa Insights Into The Bile Duct Cancer Pipeline Drugs Market, Download A Free Report Sample
Bile Duct Cancer Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for Bile Duct Cancer pipeline drugs are injection, oral, topical, suppository, and inhalational.
Bile Duct Cancer Pipeline Drugs Analysis, by Routes of Administration
Buy the Full Report for More Routes of Administration Insights For Bile Duct Cancer Pipeline Drugs Market, Download A Free Report Sample
Bile Duct Cancer Pipeline Drugs Segmentation by Molecule Type
The BDC pipeline comprises of almost equal number of small molecules and biologics. The oligonucleotide is another significant molecule type in the pipeline drugs for Bile Duct Cancer.
Bile Duct Cancer Pipeline Drugs Analysis, by Molecule Types
Buy The Full Report for More Molecule Type Insights into The Bile Duct Cancer Pipeline Drugs Market, Download A Free Report Sample
Top Sponsors in the Bile Duct Cancer Marketed and Pipeline Drugs Market
Some of the top sponsors in the Bile Duct Cancer marketed and pipeline drugs market are National Cancer Institute US, Eli Lilly and Co, Sun Yat-Sen University, F. Hoffmann-La Roche Ltd, Hutchison MediPharma Ltd, Zhongshan Hospital, AstraZeneca Plc, Fudan University, and Bayer AG.
Scope
GlobalData’s Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the BDC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BDC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for Bile Duct Cancer marketed drugs?
The key mechanisms of action for BDC marketed drugs are enzyme inhibitor, genes, nucleic acids & related components inhibitor, receptor inhibitor, protein & peptide inhibitor, and receptor antagonist.
-
What are the key routes of administration for Bile Duct Cancer marketed drugs?
The key routes of administration for Bile Duct Cancer marketed drugs are injection, oral, and topical.
-
What are the key molecule types for Bile Duct Cancer marketed drugs?
The key molecule types for Bile Duct Cancer marketed drugs are small molecule and biologic.
-
What are the key mechanisms of action for Bile Duct Cancer pipeline drugs?
The key mechanisms of action in the Bile Duct Cancer pipeline drugs market are enzyme inhibitor, cytotoxic, protein & peptide inhibitor, receptor inhibitor, receptor antagonist, receptor agonist, biological factor inhibitor, genes, nucleic acids & related components inhibitor, biological factor activator, and antigen inhibitor.
-
What are the key routes of administration for Bile Duct Cancer pipeline drugs?
The key routes of administration in the Bile Duct Cancer pipeline drugs market are injection, oral, topical, suppository, and inhalational.
-
What are the key molecule types for Bile Duct Cancer pipeline drugs?
The key molecule types in the Bile Duct Cancer pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the top sponsors for the Bile Duct Cancer marketed and pipeline drugs market?
Some of the top sponsors for the Bile Duct Cancer marketed and pipeline drugs market are National Cancer Institute US, Eli Lilly and Co, Sun Yat-Sen University, F. Hoffmann-La Roche Ltd, Hutchison MediPharma Ltd, Zhongshan Hospital, AstraZeneca Plc, Fudan University, and Bayer AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.